Long-Term Fexofenadine Use in Allergic Rhinitis and Urticaria

Indications and Treatment Strategies

The American Academy of Allergy, Asthma, and Immunology recommends continuous treatment for perennial allergic rhinitis, as intermittent dosing is less effective due to ongoing allergen exposure 1
Patients with year-round symptoms from indoor allergens require continuous antihistamine therapy, as environmental control measures alone are often insufficient 1, 2
The American College of Allergy, Asthma, and Immunology suggests maintaining daily fexofenadine throughout the year for perennial symptoms with seasonal exacerbations, potentially increasing dose or adding intranasal corticosteroids during peak seasons 1
When patients decline allergen immunotherapy, long-term antihistamine use becomes the primary management strategy, according to the American Academy of Allergy, Asthma, and Immunology 2, 3

Fexofenadine has a superior safety profile for extended therapy, being truly non-sedating even at higher-than-approved doses, with no cardiac toxicity or QT prolongation, and an adverse event profile identical to placebo in long-term studies 4, 5
The American Academy of Allergy, Asthma, and Immunology notes that fexofenadine is particularly advantageous in elderly patients, with no psychomotor impairment or fall risk associated with first-generation agents 4, 5
For patients with uncontrolled symptoms after 1 year of optimal medical management, the American College of Allergy, Asthma, and Immunology recommends evaluating for allergen immunotherapy, which may prevent new sensitizations and reduce asthma development risk 2, 3, 8

The American Academy of Allergy, Asthma, and Immunology recommends continuing therapy as long as symptoms persist, typically meaning year-round treatment for perennial conditions 1

If nasal congestion is prominent, fexofenadine alone has limited efficacy, and intranasal corticosteroids should be added, according to the American College of Allergy, Asthma, and Immunology 7, 5
Patients should be advised to avoid discontinuing effective therapy prematurely during asymptomatic periods in perennial disease, to prevent symptom recurrence, as emphasized by the American Academy of Allergy, Asthma, and Immunology 1